Optimal Medical Treatment Under-used in Vascular Peripheral Disease

Less than half of patients undergoing endovascular revascularization for peripheral artery disease to their lower limbs are discharged with optimal medical treatment. 

Subutilización del tratamiento médico en enfermedad vascular periférica

Their traditional risk factors are predictors of a more comprehensive treatment; however, women, patients with higher risk of thrombosis, and those more likely to lose a lower limb, are far from being treated optimally.

When reading these outcomes, we tend to believe most physicians think women are not at risk and, on the opposite side of the spectrum, those at risk of amputation are too far gone to even try.

The aim of this study was to look into indications at discharge of patients treated with lower limb endovascular intervention.

According to guidelines, optimal medical treatment is prescribed at discharge when patients are under antiplatelet therapy, statins and one inhibitor of the angiotensin convertor enzyme (ACEI) or an angiotensin receptor blocker (ARB). 


Read also: More Evidence for Short Term DAPT: Approaching “the Class Effect”.


Of the 12316 patients included, only 47.4% (n=5844) were discharged with optimal medical treatment. Most patients were on antiaggregants (95.2%), many on statins (83.5%) and a few on ACEI or ARB (55.8%).

80.5% of patients had a class I indication for antiaggregants. 

At multivariable analysis, it was seen that female sex, old age, kidney failure, critical lower limb ischemia, and cardiac failure were predictors of NO optimal medical treatment, against guideline recommendation. 


Read also: Pleiotropic Effect of Metoprolol: Different From other B-blockers.


On the flipside, hypertension, diabetes, heart disease and revascularization procedures were positive predictors of optimal medical treatment. 

Conclusion

Less than half of patients undergoing endovascular lower limb revascularization are discharged with optimal medical treatment against guideline recommendation. Both patients and physicians should make a serious effort to close this gap.  

Original Title: Predictors of Underutilization of Medical Therapy in Patients Undergoing Endovascular Revascularization for Peripheral Artery Disease.

Reference: S. Elissa Altin et al. J Am Coll Cardiol Intv 2020;13:2911–8.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...